date:Sep 15, 2012
nfection that might be caused by contamination. In the post-marketing surveillance of ImmuCyst, patients who receive ImmuCyst are under active medical supervision and as such, any possible health impacts related to the manufacturing problems would be identified by their health care practitioner.
Sanofi Pasteur has informed Health Canada of its decision to temporarily suspend manufacturing in order to renovate the facility where ImmuCyst is manufactured to improve the quality of the environment